Methylthionine (AC), tetramethylthionine (MB), thionin (TN) and myricetin were purchased from Sigma and suspended in dimethylsulfoxide (DMSO). The dihydropyrimidines 115-7c and SW02 were synthesized as described (Wisen et al., 2008 (link)). Epoxomicin and 17-AAG were acquired from A.G. Scientific. All clones were in the pcDNA3.1 vector. SiRNAs (Qiagen) were transfected at 20 nM. All antibodies were diluted in 5% NFDM in TBST at 1:1000 with the exception of pS396/S404 tau, which was used at 1:100. Where pTau is indicated, pS396/S404 was the antibody used. PHF1 (pS396/S404 tau) was provided by Dr. Peter Davies. 12E8 (pS262/S356 tau) was provided by Dr. Peter Seubert. The following antibodies were purchased from the company indicated in parentheses; α-synuclein (Cell Signaling), TDP43 (Protein Tech), Hsp70 and HSF1 (Assay Designs), HA (Roche), Actin (Sigma Aldrich), Hsp40 (BD Transduction Labs), Hsp27 and total tau (Santacruz Biotech). All cell lines were maintained according to ATCC guidelines. Stably transfected HeLa cells over-expressing wildtype 4R0N human tau were generated by clonal selection with G418 (Invitrogen).